CELC — Celcuity Inc.
—
Nasdaq ·
Health Care ·
Health Care Providers & Services ·
CIK 1603454 ·
Last close
$90.79
Market Cap
$4.44B
52W High
$140.85
52W Low
$78.60
ADV30
1,398,274
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -50,507,000 | -52,841,000 | 410,164,000 | 145,191,000 | 356,639,000 |
| Dec 2025 | 0 | — | -49,201,000 | -50,973,000 | 466,558,000 | 165,703,000 | 366,003,000 |
| Sep 2025 | 0 | — | -42,849,000 | -43,804,000 | 476,004,000 | 74,252,000 | 359,041,000 |
| Jun 2025 | 0 | — | -44,009,000 | -45,268,000 | 183,592,000 | 46,354,000 | 139,217,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-172,492,000
Investing CF
$-53,827,000
Financing CF
$355,032,000
CapEx
$-474,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.90
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-501,738,000
Inventory
—
Receivables
$1,600,621
ST Investments
$241,873,000
EBIT TTM
$-172,836,000
Pretax Income TTM
$-192,886,000
Interest Exp TTM
$20,050,000
Analysts
11
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -172,192,000 | -177,042,000 | 466,558,000 | 366,003,000 | — | -153,280,000 |
| Dec 2024 | 0 | -113,267,000 | -111,779,000 | 245,123,000 | 129,504,000 | — | -83,467,000 |
| Dec 2023 | 0 | -66,230,331 | -63,779,116 | 191,219,398 | 51,450,076 | — | -53,812,253 |
| Dec 2022 | 0 | -39,391,091 | -40,370,040 | 175,697,097 | 41,925,630 | — | -36,008,171 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.08
Max Pain — expiry 2026-09-18
max pain strike: $120.00 · spot: $93.34 · call oi: 4,387 · put oi: 7,267
Expected Move to 2026-09-18:
±$12.30
(13.18%) —
implied range
$81.04 –
$105.64
· ATM straddle on $95.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CON | Concentra Group Holdings Parent, Inc. | $4.46B | $34.99 | — |
| LFST | LifeStance Health Group, Inc. | $4.65B | $12.16 | — |
| BLLN | BillionToOne, Inc. | $4.13B | $96.74 | — |
| SHC | Sotera Health Co | $5.47B | $19.17 | — |
| NHC | NATIONAL HEALTHCARE CORP | $3.58B | $228.38 | — |
News headlines (Yahoo Finance, 1h cache)
Celcuity (CELC) Q2 2026 Earnings Call Transcript
2026-08-20 21:14 · Yahoo
Is Celcuity (CELC) A Bargain As Losses Widen Ahead Of Its First Launch?
2026-08-16 06:11 · Yahoo
How Investors May Respond To Celcuity (CELC) Winning FDA Nod For Revtopik Amid Wider Quarterly Loss
2026-08-16 04:16 · Yahoo
Celcuity Inc (CELC) (Q2 2026) Earnings Call Highlights: FDA Approval and Commercial Launch ...
2026-08-14 05:02 · Yahoo
Celcuity Q2 Earnings Call Highlights
2026-08-13 23:04 · Yahoo
Celcuity Schedules Release of Second Quarter 2026 Financial Results and Webcast/Conference Call
2026-08-06 12:34 · Yahoo
Newly FDA-Approved REVTORPYK™ (gedatolisib) Included in the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines for HR+/HER2- Locally Advanced or Metastatic Breast Cancer
2026-07-30 12:30 · Yahoo
Why This Biotech Stock, With Its First FDA Approval, Just Crashed By Double Digits
2026-07-15 20:16 · Yahoo
Celcuity gains FDA approval for closely watched breast cancer drug
2026-07-15 12:18 · Yahoo
Celcuity Enters Commercial Stage as FDA Approves REVTORPYK for Advanced Breast Cancer
2026-07-15 08:02 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.